Jacobson Center for Clinical & Translational Research

Main Menu


Additional Information


Contact Us

Rheumatology Research

Study Title:  Pulmonary Arterial Hypertension (PAH) in scleroderma patents Quality Enhancement Research Initiative (QuERI) Extension Program. (Identifier: NCT01389206)

Study Purpose:  This program intends to improve the management of pulmonary arterial hypertension (PAH) patients through an evidence-based approach aimed at achieving optimal World Health Organization (WHO) functional class (FC): 1. Improving FC III & IV patients to FC II, 2. Improving FC II patients to FC I, and 3. Maintaining FC II & FC I patients.

Principal Investigator: Bashar Kahaleh, M.D.

Study Coordinator: Jennifer Gilmore, RN, for more information, please contact 419.383.6761.

Study Title:  A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-220 in Subjects with Systemic Lupus Erythematosus (Identifier: NCT02185040)

Study Purpose:  The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.

Principal Investigator: Bashar Kahaleh, M.D.

Study Coordinator: Jennifer Gilmore, RN, for more information, please contact 419.383.6761.

Study Title:  A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis (ASSET).  (Identifier: NCT02161406)

Study Purpose:  The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan Score [mRSS]) in patients with diffuse cutaneous systemic sclerosis (dcScc) comparead to matching placebo.

Principal Investigator: Bashar Kahaleh, M.D.

Study Coordinator:  Jennifer Gilmore, RN, 419.383.6761

Study Title:  A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantiboy-Positsive Systemic Lupus Erythematous Treated with or without Benlysta™ (SABLE).  (Identifier: NCT01729455)

Study Purpose:  The purpose of this registry is to collect additional information regarding the side effects and effectiveness of BENLYSTA™ (belimumab) when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE). Information will be collected on serious events that are not that common or may only be seen with long-term treatment. These events include death, cancers, serious infections and other infections of interest, and serious mental health problems. Information on the effectiveness of BENLYSTA™ will also be collected.

Principal Investigator: Nezam Altorok, M.D.

Study Coordinator:  Jennifer Gilmore, RN, 419.383.6761

Last Updated: 8/25/15